ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Thursday, 12 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Anupam Rasayan India Earnings Call: Key Takeaways

Anupam Rasayan announced the acquisition of Bliss GVS Pharma (43.3-48.2% stake plus open offer) to expand into pharmaceutical formulations and regulated markets like the USA.

Highlights
Revenue growthFY26 Revenue ₹927cr, growing from ₹810cr in FY25.
MarginsEBITDA margins improved from 16% to 18% in FY26.
Demand visibilitySupported by long-standing distributor relationships and 150+ brands.
Management confidenceStrong focus on synergies and USA footprint expansion.

Growth

Bliss GVS FY26 Revenue at ₹927cr (14.4% YoY), EBITDA ₹164cr (18% margin), and PAT ₹135cr (50% YoY).

Outlook

Ongoing Capex of ₹250cr for Halol facility; targeting entry into regulated markets with a pipeline of 62+ molecules.

Risks

Low capacity utilization (currently 30%); expansion depends on successful integration and penetration of highly regulated Western markets.

Source

Earnings Call filed with BSE, NSE: ANURAS. Summary written with AI assistance from the document.

Read the document ↗

Anupam Rasayan India Ltd: key numbers

Share price
₹1,196.20
Market cap
₹13,619 Cr
Revenue (annual)
₹2,365 Cr
Net profit (annual)
₹170.1 Cr
P/E (TTM)
75.5×Sector 35.5×
Promoter holding
59.07%+0.00% QoQ
FII holding
8.65%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Anupam Rasayan India Ltd

All →